Bouazzaoui Abdellatif, Abdellatif Ahmed A H
Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, P.O. Box 715, Makkah 21955, Saudi Arabia.
Science and Technology Unit, Umm Al Qura University, P.O. Box 715, Makkah 21955, Saudi Arabia.
Vaccine X. 2024 May 24;19:100500. doi: 10.1016/j.jvacx.2024.100500. eCollection 2024 Aug.
Since the first use of vaccine tell the last COVID-19 pandemic caused by spread of SARS-CoV-2 worldwide, the use of advanced biotechnological techniques has accelerated the development of different types and methods for immunization. The last pandemic showed that the nucleic acid-based vaccine, especially mRNA, has an advantage in terms of development time; however, it showed a very critical drawback namely, the higher costs when compared to other strategies, and its inability to protect against new variants. This showed the need of more improvement to reach a better delivery and efficacy. In this review we will describe different vaccine delivery systems including, the most used viral vector, and also variable strategies for delivering of nucleic acid-based vaccines especially lipid-based nanoparticles formulation, polymersomes, electroporation and also the new powerful tools for the delivery of mRNA, which is based on the use of cell-penetrating peptides (CPPs). Additionally, we will also discuss the main challenges associated with each system. Finlay, the efficacy and safety of the vaccines depends not only on the formulations and delivery systems, but also the dosage and route of administration are also important players, therefore we will see the different routes for the vaccine administration including traditionally routes (intramuscular, Transdermal, subcutaneous), oral inhalation or via nasal mucosa, and will describe the advantages and disadvantage of each administration route.
自首次使用疫苗对抗由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)传播引发的全球新冠疫情以来,先进生物技术的应用加速了不同类型免疫方法的开发。上一次疫情表明,基于核酸的疫苗,尤其是信使核糖核酸(mRNA)疫苗,在开发时间上具有优势;然而,它也显示出一个非常关键的缺点,即与其他策略相比成本更高,且无法抵御新变种。这表明需要进一步改进以实现更好的递送和效果。在这篇综述中,我们将描述不同的疫苗递送系统,包括最常用的病毒载体,以及递送基于核酸的疫苗的各种策略,特别是基于脂质的纳米颗粒制剂、聚合物囊泡、电穿孔,还有基于细胞穿透肽(CPPs)使用的强大的mRNA递送新工具。此外,我们还将讨论与每个系统相关的主要挑战。最后,疫苗的有效性和安全性不仅取决于制剂和递送系统,给药剂量和途径也是重要因素,因此我们将探讨疫苗给药的不同途径,包括传统途径(肌肉注射、经皮、皮下)、口服吸入或通过鼻黏膜给药,并描述每种给药途径的优缺点。
Vaccines (Basel). 2021-5-19
mSystems. 2023-4-27
Curr Pharm Biotechnol. 2014
Acc Chem Res. 2021-12-7
Nat Aging. 2025-8
Vaccines (Basel). 2025-6-26
Cell Mol Immunol. 2025-7-9
Vaccines (Basel). 2025-4-27
Front Public Health. 2023
Vaccines (Basel). 2023-4-1
J Am Chem Soc. 2023-3-15
Iran J Pharm Res. 2022-5-9
N Engl J Med. 2022-6-2
Pharmaceutics. 2021-12-29